203 related articles for article (PubMed ID: 26022160)
21. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?
Kodidela S; Suresh Chandra P; Dubashi B
Eur J Clin Pharmacol; 2014 Mar; 70(3):253-60. PubMed ID: 24370659
[TBL] [Abstract][Full Text] [Related]
24. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
den Hoed MA; Lopez-Lopez E; te Winkel ML; Tissing W; de Rooij JD; Gutierrez-Camino A; Garcia-Orad A; den Boer E; Pieters R; Pluijm SM; de Jonge R; van den Heuvel-Eibrink MM
Pharmacogenomics J; 2015 Jun; 15(3):248-54. PubMed ID: 25348617
[TBL] [Abstract][Full Text] [Related]
25. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.
Stamp LK; Roberts RL
Pharmacogenomics; 2011 Oct; 12(10):1449-63. PubMed ID: 22008049
[TBL] [Abstract][Full Text] [Related]
26. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V
Toxicol Sci; 2014 Nov; 142(1):196-209. PubMed ID: 25124723
[TBL] [Abstract][Full Text] [Related]
27. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL.
Dulucq S; St-Onge G; Gagné V; Ansari M; Sinnett D; Labuda D; Moghrabi A; Krajinovic M
Blood; 2008 Apr; 111(7):3692-700. PubMed ID: 18096764
[TBL] [Abstract][Full Text] [Related]
28. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia.
Iparraguirre L; Gutierrez-Camino A; Umerez M; Martin-Guerrero I; Astigarraga I; Navajas A; Sastre A; Garcia de Andoin N; Garcia-Orad A
Pharmacogenet Genomics; 2016 Nov; 26(11):517-525. PubMed ID: 27649261
[TBL] [Abstract][Full Text] [Related]
29. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.
Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
Leuk Res; 2018 Feb; 65():61-66. PubMed ID: 29306656
[TBL] [Abstract][Full Text] [Related]
30. Cancer research: from folate antagonism to molecular targets.
Bertino JR
Best Pract Res Clin Haematol; 2009 Dec; 22(4):577-82. PubMed ID: 19959110
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate induces astrocyte apoptosis by disrupting folate metabolism in the mouse juvenile central nervous system.
Shao Y; Tan B; Shi J; Zhou Q
Toxicol Lett; 2019 Feb; 301():146-156. PubMed ID: 30502384
[TBL] [Abstract][Full Text] [Related]
32. Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia.
Koomdee N; Hongeng S; Apibal S; Pakakasama S
Asian Pac J Cancer Prev; 2012; 13(7):3461-4. PubMed ID: 22994778
[TBL] [Abstract][Full Text] [Related]
33. Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway.
Chaabane S; Marzouk S; Akrout R; Ben Hamad M; Achour Y; Rebai A; Keskes L; Fourati H; Bahloul Z; Maalej A
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):385-93. PubMed ID: 26077125
[TBL] [Abstract][Full Text] [Related]
34. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.
Takatori R; Takahashi KA; Tokunaga D; Hojo T; Fujioka M; Asano T; Hirata T; Kawahito Y; Satomi Y; Nishino H; Tanaka T; Hirota Y; Kubo T
Clin Exp Rheumatol; 2006; 24(5):546-54. PubMed ID: 17181924
[TBL] [Abstract][Full Text] [Related]
35. Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia.
Faganel Kotnik B; Dolzan V; Grabnar I; Jazbec J
Leuk Lymphoma; 2010 Apr; 51(4):724-6. PubMed ID: 20141435
[No Abstract] [Full Text] [Related]
36. PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy.
Smid A; Karas-Kuzelicki N; Jazbec J; Mlinaric-Rascan I
Sci Rep; 2016 Jul; 6():30244. PubMed ID: 27452984
[TBL] [Abstract][Full Text] [Related]
37. Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
J Pediatr Hematol Oncol; 2017 Nov; 39(8):589-595. PubMed ID: 28719513
[TBL] [Abstract][Full Text] [Related]
38. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia.
Costea I; Moghrabi A; Laverdiere C; Graziani A; Krajinovic M
Haematologica; 2006 Aug; 91(8):1113-6. PubMed ID: 16870553
[TBL] [Abstract][Full Text] [Related]
39. Influence of variants in folate metabolism genes on 6-mercaptopurine induced toxicity during treatment for childhood acute lymphocytic leukemia.
Milosevic G; Kotur N; Lazic J; Krstovski N; Stankovic B; Zukic B; Janic D; Jurisic V; Pavlovic S; Dokmanovic L
J BUON; 2019; 24(5):2075-2083. PubMed ID: 31786878
[TBL] [Abstract][Full Text] [Related]
40. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
Kager L; Cheok M; Yang W; Zaza G; Cheng Q; Panetta JC; Pui CH; Downing JR; Relling MV; Evans WE
J Clin Invest; 2005 Jan; 115(1):110-7. PubMed ID: 15630450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
